With the continuous expansion of the Chinese medicine formula granule test market, two major issues cannot be ignored

On November 1, the State Food and Drug Administration and other departments ended the more than 20-year pilot work of traditional Chinese medicine formula granules, and officially launched the registration module of traditional Chinese medicine formula granules
.
In this regard, the analysis believes that this breaks the original market pattern and will further promote the development of the Chinese medicine formula granule market
.
It is understood that in recent years, the compound annual growth rate of Chinese medicine formula particles has reached about 15%, far exceeding the average development speed of 4% of China's pharmaceutical industry.
With the end of the pilot work of Chinese medicine formula particles, the size and development trend of the future market Both will be more worth looking forward to
.
In addition, with the liberalization of this policy, after companies are no longer subject to license restrictions, the number of entry will continue to increase
.
According to data, during the 20-year pilot period, in addition to six national pilot companies (Jiangyin Tianjiang Pharmaceutical, China Resources Sanjiu Modern Chinese Medicine, Guangdong Yifang Pharmaceutical Co.
, Ltd.
, Sichuan New Green Pharmaceutical, Beijing Kangrentang Pharmaceutical, Nanning In addition to Peili Pharmaceuticals), many companies in many provinces have obtained the qualification of provincial-level Chinese medicine formula granules pilots
.
Up to now, dozens of new enterprises have obtained the pilot qualifications of various Chinese medicine formula granules in various provinces, municipalities and autonomous regions across the country
.
Among them, more than 30 A-share listed companies have deployed or are about to deploy traditional Chinese medicine formula particles
.
From an overall point of view, the industry predicts that as the number of entrants continues to increase, the industry market scale will continue to expand in the future, and it is expected to usher in several times the room for growth
.
At the same time, as the sales scope has been expanded from more than 2500 TCM hospitals of second-level and above to tens of thousands of qualified medical institutions, the scope of use of TCM formula granules will also greatly increase, and the industry may maintain a relatively high growth rate in the future, and welcome Come more new changes
.
At present, many companies are actually accelerating their deployment in the face of the ever-opening market of traditional Chinese medicine formula granules
.
When the former investor asked about the impact of Kangrentang’s traditional Chinese medicine formula granule business after the pilot liberalization, its staff said that Kangrentang, as one of the earlier national pilot enterprises of traditional Chinese medicine formula granules, has been working Participate in the formulation of industry standards, industrial chain layout, varieties, channels, and quality first-mover advantages
.
In the future, the company will continue to promote the formulation and application of national and provincial standards, guide the formulation and coordination of the provincial standards of Beijing formula granules, and jointly complete more than 100 varieties of standard research with other companies, and simultaneously promote 10 classic Chinese medicine prescriptions as planned The development work of the company guarantees the company's continued competitiveness in terms of products
.
Although the end of the pilot work of traditional Chinese medicine formulation particles is currently bringing more opportunities to the entire industry, the industry has also pointed out that there are two major issues that need to be paid attention to
.
The first is that the end of the trial does not mean that the regulation of TCM formula particles will be relaxed.
On the contrary, the drug supervision and administration department will strengthen the local supervision in accordance with the "four strict" requirements, and strive to strengthen the supervision during and after the event
.
In addition, on August 9 this year, the National Medical Insurance Administration responded to the "Recommendations on Accelerating the Entry of Chinese Medicines and Formula Granules into Centralized Procurement", stating that the next step will be to speed up the inclusion of proprietary Chinese medicines and formula granules into centralized procurement
.
Generally speaking, centralized procurement actually means lowering prices
.
In this regard, industry analysts believe that once formula particles are included in centralized procurement, a number of small and medium-sized enterprises may be eliminated under the background of superimposed strict supervision, and giant enterprises with scale and cost advantages may usher in more opportunities
.